Selenium, Stroke, and Infection: A Threefold Relationship; Where Do We Stand and Where Do We Go?

被引:5
|
作者
Liampas, Andreas [1 ]
Zis, Panagiotis [2 ]
Hadjigeorgiou, Georgios [3 ]
Vavougios, George D. [3 ]
机构
[1] Nicosia New Gen Hosp, Dept Neurol, CY-2029 Nicosia, Cyprus
[2] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Neurol 2, Athens 12462, Greece
[3] Univ Cyprus, Med Sch, CY-2024 Nicosia, Cyprus
关键词
selenium; coagulation; ischemic stroke; infection; ACUTE ISCHEMIC-STROKE; TO-LYMPHOCYTE RATIO; LUNG-CANCER RISK; SERUM SELENIUM; DIETARY SELENIUM; GLOBAL BURDEN; SELENOCYSTEINE INCORPORATION; GLUTATHIONE-PEROXIDASE; MYOCARDIAL-INFARCTION; INFLAMMATORY RESPONSE;
D O I
10.3390/nu15061405
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Stroke is currently the second most common cause of death worldwide and a major cause of serious long-term morbidity. Selenium is a trace element with pleotropic effects on human health. Selenium deficiency has been associated with a prothrombotic state and poor immune response, particularly during infection. Our aim was to synthesize current evidence on the tripartite interrelationship between selenium levels, stroke, and infection. Although evidence is contradictory, most studies support the association between lower serum selenium levels and stroke risk and outcomes. Conversely, limited evidence on the role of selenium supplementation in stroke indicates a potentially beneficial effect of selenium. Notably, the relationship between stroke risk and selenium levels is bimodal rather than linear, with higher levels of serum selenium linked to disturbances of glucose metabolism and high blood pressure, morbidities which are, in turn, substrates for stroke. Another such substrate is an infection, albeit forming a bidirectional relationship with both stroke and the consequences of impaired selenium metabolism. Perturbed selenium homeostasis leads to impaired immune fitness and antioxidant capacity, which both favor infection and inflammation; specific pathogens may also contend with the host for transcriptional control of the selenoproteome, adding a feed-forward loop to this described process. Broader consequences of infection such as endothelial dysfunction, hypercoagulation, and emergent cardiac dysfunction both provide stroke substrates and further feed-forward feedback to the consequences of deficient selenium metabolism. In this review, we provide a synthesis and interpretation of these outlined complex interrelationships that link selenium, stroke, and infection and attempt to decipher their potential impact on human health and disease. Selenium and the unique properties of its proteome could provide both biomarkers and treatment options in patients with stroke, infection, or both.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [2] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    SKELETAL MUSCLE, 2011, 1
  • [3] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [4] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [5] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    Skeletal Muscle, 1
  • [6] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [7] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [8] THE CYTOGENETICS OF RENAL TUMORS - WHERE DO WE STAND, WHERE DO WE GO
    WALTER, TA
    BERGER, CS
    SANDBERG, AA
    CANCER GENETICS AND CYTOGENETICS, 1989, 43 (01) : 15 - 34
  • [9] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    PIMA MAGAZINE, 1994, 76 (03): : S2 - S3
  • [10] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142